Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Public Health
Published in: International Journal of Public Health 3/2019

01-04-2019 | Editorial

Seeking to introduce a pharmacoeconomics framework in Cyprus

Author: Panagiotis Petrou

Published in: International Journal of Public Health | Issue 3/2019

Login to get access

Excerpt

Health agencies face an array of profound challenges. Among them, the need to exert control over surging pharmaceutical expenditures is imperative (Dubois et al. 2000). If pharmaceutical expenditure is left unchecked, it threatens to jeopardise health systems’ fiscal sustainability and violate equity and solidarity, which are fundamental principles in health care provision. Pharmaceutical care has significantly contributed towards life’s expectancy increase and morbidity reduction, so health agencies must balance the need to keep affordable prices and give patients access to innovative products (Lichtenberg 2012). …
Literature
Dias S, Welton NJ, Sutton AJ et al (2013) Evidence synthesis for decision making 1: introduction. Med Decis Mak 33(5):597–606CrossRef
Dubois RW, Chawla AJ, Neslusan CA et al (2000) Explaining drug spending trends: does perception match reality? Health Aff 19(2):231–239CrossRef
Flume M, Bardou M, Capri S et al (2016) Feasibility and attractiveness of indication value-based pricing in key EU countries. J Mark Access Health Policy 4(1):1–6
Lichtenberg FR (2012) The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001–2007. PharmacoEconomics 30(3):197–221CrossRefPubMed
Petrou P, Talias M (2013) A framework for applying health technology assessment in Cyprus: thoughts, success stories, and recommendation. Value Health Reg Issues 2:273–278CrossRefPubMed
Petrou P, Talias M (2014) A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer. Cost Eff Resour Alloc 12(12):1–11
Metadata
Title
Seeking to introduce a pharmacoeconomics framework in Cyprus
Author
Panagiotis Petrou
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
International Journal of Public Health / Issue 3/2019
Print ISSN: 1661-8556
Electronic ISSN: 1661-8564
DOI
https://doi.org/10.1007/s00038-018-1161-z

Other articles of this Issue 3/2019

International Journal of Public Health 3/2019 Go to the issue

Original Article

Childhood vaccination in Kenya: socioeconomic determinants and disparities among the Somali ethnic community

Original Article

A comparison of information sharing behaviours across 379 health conditions on Twitter

Original Article

Residential moves and its association with substance use, healthcare needs, and acute care use among homeless and vulnerably housed persons in Canada

Review

Indigenous women’s access to maternal healthcare services in lower- and middle-income countries: a systematic integrative review

Original Article

Analysis of non-compliance with smoke-free legislation in Russia

Original Article

Linked factors to access to sexual health checkups of female sex workers in the metropolitan region of Chile